Lynparza PROpel trial meets primary endpoint
This announcement contains inside information24 September 2021 07:00 BST Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in1st-line metastatic castration-resistant prostate cancer First PARP inhibitor to demonstrate clinical benefit incombination with a new hormonal agent in this setting Positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful